Neuroendocrine differentiation in carcinoma of the prostate: An institutional review.

Pérez, David; Linares, Estefanía; Almagro, Elena; Cantos, Blanca; Méndez, Míriam; Maximiano, Constanza; Franco, F.; Rubio, Judit; Palka, Magda; Calvo, Virginia; Ramírez, Patricia; Salas, Clara; Carballido, Joaquı́n; Provencio, Mariano

doi:10.1200/jco.2014.32.15_suppl.e16109

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 2014 ASCO Genitourinary Cancers Symposium, Perez et al investigated for the presence of NE differentiation in a series of 450 patients with PCa. Only three patients presented NE differentiation [80]. On the other hand, Jimenez and his colleagues [81] evaluated the NE differentiation patterns in 237 metastatic sites from 187 patients with PCa or poorly differentiated carcinomas.…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives

Santoni

Conti

Burattini

et al. 2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives

Santoni

Conti

Burattini

et al. 2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

“…The reported prevalence of NePC has varied between studies, possible due to limitations in targeted tissue sampling and heterogeneous disease penetrance. For example, in a study of 450 patients with mCRPC by Perez et al, only 3 patients demonstrated NePC differentiation [4], whereas Jimenez et al found NePC differentiation in 92/237 metastatic biopsies from 79 of 187 patients with mCRPC. [5].…”

Section: Introductionmentioning

confidence: 98%

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with 68Ga DOTATATE PET-CT

Bilen¹,

Akintayo²,

Liu³

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives: Prostate cancer is well known to express high levels of somatostatin receptors and preliminary data suggests that PET imaging with the somatostatin analog, 68Ga-DOTATATE, may allow for whole body staging of patients with metastatic castration resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NePC). This study explores the utility of 68Ga-DOTATATE PET-CT to identify metastatic deposits in men with mCRPC and NePC and prognosticate disease progression. Methods: 68Ga-DOTATATE PET-CT was performed in 17 patients with mCRPC and of those 2/17 had NePC. Semiquantitative analysis with standardized uptake values (SUV) (e.g. SUVmax, SUVmean) was performed for each metastatic lesion and reference background tissues. 68Ga-DOTATATE uptake in metastatic deposits was further classified as: mild (less than liver), moderate (up to liver average), or marked (greater than liver). Serial prostate-specific antigen measurements and patient survival were followed up to 3 years after PET imaging to assess response to standard of care treatment. Results: All patients had at least one metastic lesion with identifiable 68Ga-DOTATATE uptake. Marked 68Ga-DOTATATE uptake was found in 7/17 patients, including both NePC patients, and all were non-responders to systemic therapy and died within the follow up period, with a mean time to death of 8.1 months. 3 patients had mild 68Ga-DOTATATE uptake, and all were responders to systemic therapy and were alive 36 months after 68Ga-DOTATATE imaging. Conclusions: 68Ga-DOTATATE is able to identify mCRPC and NePC metastatic deposits, and lesions with 68Ga-DOTATATE uptake > liver may portend poor outcomes in patients with mCRPC.

show abstract

“…The reported prevalence of NePC has varied between studies, possibly due to limitations in targeted tissue sampling and heterogeneous disease penetrance. For example, in a study of 450 patients with mCRPC by Perez et al, only 3 patients demonstrated NePC differentiation [ 4 ], whereas Jimenez et al found NePC differentiation in 92/183 metastatic biopsies from 79 of 157 patients with mCRPC [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT

Bilen

Akintayo

Liu

et al. 2022

Cancers

View full text Add to dashboard Cite

Objectives: Prostate cancer is well known to express high levels of somatostatin receptors and preliminary data suggests that PET imaging with the somatostatin analog, [68Ga]Ga-DOTATATE, may allow for whole body staging of patients with metastatic castration resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NePC). This study explores the utility of [68Ga]Ga-DOTATATE PET-CT to identify metastatic deposits in men with mCRPC and NePC and prognosticate disease progression. Methods: [68Ga]Ga-DOTATATE PET-CT was performed in 17 patients with mCRPC and of those, 2/17 had NePC. A semiquantitative analysis with standardized uptake values (SUV) (e.g., SUVmax, SUVmean) was performed for each metastatic lesion and reference background tissues. [68Ga]Ga-DOTATATE uptake in metastatic deposits was further classified as: mild (less than liver), moderate (up to liver average), or marked (greater than liver). Serial prostate-specific antigen measurements and patient survival were followed up to 3 years after PET imaging to assess response to standard of care treatment. Results: All patients had at least one metastatic lesion with identifiable [68Ga]Ga-DOTATATE uptake. Marked [68Ga]Ga-DOTATATE uptake was found in 7/17 patients, including both NePC patients, and all were non-responders to systemic therapy and died within the follow up period, with a mean time to death of 8.1 months. Three patients had mild [68Ga]Ga-DOTATATE uptake, and all were responders to systemic therapy and were alive 36 months after [68Ga]Ga-DOTATATE imaging. Conclusions: [68Ga]Ga-DOTATATE is able to identify mCRPC and NePC metastatic deposits, and lesions with [68Ga]Ga-DOTATATE uptake > liver may portend poor outcomes in patients with mCRPC.

show abstract

Neuroendocrine differentiation in carcinoma of the prostate: An institutional review.

Cited by 3 publications

References 22 publications

Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives

Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with 68Ga DOTATATE PET-CT

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [68Ga]Ga DOTATATE PET-CT

Contact Info

Product

Resources

About